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 The purpose of this commentary is to re-evaluate the historic and 
scientific facts on Ebola haemorrhagic fever and the role of the 
international community, especially Economic Community of West 
African States (ECOWAS) in stemming the tide. It rehashes the argument 
on causes and prevention and draws attention of readers to emphasize the 
need for establishment of airport, sea port and border health posts with 
well drilled and efficient health professionals to be able to test, detect and 
quarantine persons with Ebola and treat them to prevent the spread of the 
disease from infected persons to primary or first contacts and secondary 
contacts. Significantly, countries in the West African sub-region are 
alarmed by the potential spread of the disease to countries that have 
hitherto been free of the disease. The potential global threat of the disease 
has been analysed and measures to be taken by countries within the  
West-African sub-region have been emphasized. This notwithstanding, 
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1. INTRODUCTION  
Ebola Haemorrhagic Fever (EHF), commonly known as Ebola Virus Disease (EVD) is known to be 
one of the numerous Viral Haemorrhagic Fevers (VHF). It is a severe, often fatal disease in humans and 
nonhumans such as monkeys, gorillas, and chimpanzees. Ebola Virus Disease (EVD) has been proven to be 
caused by the infection of a virus in the family of Filoviridae and genus of Ebolavirus. It has been noted that 
when an infection occurs, symptoms mostly begin shortly [1] (Centres for Disease Control and Infection, 
accessed; March 2015). The first Ebola virus species was discovered in 1976 in what is now the Democratic 
Republic of Congo near the Ebola River. Since then, outbreaks have appeared sporadically [1]. 
There are five identified subspecies of Ebolavirus. Four of the five have caused diseases in humans: 
Ebola virus (Zaire ebolavirus); Sudan virus (Sudan ebolavirus); Taï Forest virus (Taï Forest ebolavirus, 
formerly Côte d’Ivoire ebolavirus); and Bundibugyo virus (Bundibugyo ebolavirus). The fifth, Reston virus 
(Reston ebolavirus), has caused disease in nonhuman primates, but not in humans. The natural reservoir hosts 
of Ebola viruses remain unknown. However, on the basis of available evidence and the nature of similar 
viruses, researchers believe that the virus is zoonotic (animal-borne) with bats being the most likely reservoir. 
Four of the five subtypes occur in animal hosts native to Africa. It has been scientifically postulated that  
a host of similar species are associated with Reston virus, which was isolated from infected cynomolgous 
monkeys imported to the United States and Italy from the Philippines. Several workers in the Philippines and 
in the US holding facility outbreaks became infected with the virus, but did not become ill [1]. 
EVD is a severe, often-fatal disease caused by infection with a species of Ebola virus. Although the 
disease is rare, it can spread from person to person, especially among health care staff and other people who 
have close contact with an infected person as expressly seen in the 2014 outbreak in Guinea, Sierra Leone, 
           ISSN: 2252-8806 
Int. J. Public Health Sci. Vol. 8, No. 1, March 2019: 1 – 13 
2
Liberia and Nigeria. Ebola is spread through direct contact with blood or body fluids (such as saliva or urine) 
of an infected person or animal or through contact with objects that have been contaminated with the blood or 
other body fluids of an infected person. The likelihood of contracting Ebola is extremely low unless a person 
has direct contact with the body fluids of a person or animal that is infected and showing symptoms.  
Close contact is defined as having cared for or lived with a person with the disease or having a high 
likelihood of direct contact with blood or body fluids of an Ebola patient. Close contact does not include 
walking by a person or briefly sitting across a room from a person. The scientific argument is that fever in  
a person who has travelled to or lived in an area where Ebola is present is likely to be caused by a more 
common infectious disease, but the person would need to be evaluated by a health care provider to be sure 
whether it is Ebola or other common fever. Again, the scientific evidence points to an incubation period, 
from exposure to when signs or symptoms appear. This ranges from two (2) to twenty-one (21) days. Early 
symptoms include sudden fever, severe headaches, and muscle aches. Around the fifth day, a skin rash can 
occur. Nausea, vomiting, chest or abdominal pain, and diarrhoea may follow. Symptoms can become 
increasingly severe and may include difficulty in breathing or swallowing, bleeding inside and outside the 
body, and multi-organ failure. It is essential to point out that the dangers associated with the diseases calls for 
a continuous education of citizens of satets in Africa and West-Africa in particular. The need for the 
behaviorial sciences to highlight the research in the field would have the tendency or the proclivity to 
accentuate the gains made thus far. A continuos inquiry toward this end can therefore not be gainsaid. 
Significantly, the 2014 EVD scourge in countries like Guinea, Liberia, Sierra Leone and Nigeria 
necessitated medical interventions, scientific research in the area of drugs and testing among others. Also of 
primary importance is the scare it sent to Africa and the global village which further necessitated institutional 
actions from independent groups and supra regional political organizations like ECOWAS. It shall remain 
expedient to continue the commentary and the discourse; perhaps, we might see the last of it. By highlighting 
key knowledge of filoviral HF, this paper will help medical workers plan basic clinical studies in future 
outbreaks, devise efficient record-keeping mechanisms, and prepare their findings for publication. In addition 
to providing a concise summary of information useful to clinicians and researchers, this perspective piece can 
also serve as a guide to the filovirus clinical literature, which varies greatly in the quantity and quality of data 
in the various case reports and descriptions of outbreaks. It also has the tendency to encourage positive public 
action toward the prevention and mitigation of the spread of the disease in the foreseeable future.  
However, of seminal importance to this discourse are the efforts of the WHO, ECOWAS and other 
external orginations as well as the efforts of the respective governments and local authorities. The narrative 
has been that which emphasizes public health and or post-colonial public health strategies to deal with the 
burgeoning questions of public health that dovetails into present efforts to deal with the Ebola question. 
Whereas the post-colonial public health literature aims at discarding the efforts of institutions of formal 
colonizers, there is still the need to re-evaluate the collective efforts of these institutions in line with the 
efforts of WHO, ECOWAS, laboritarians, medical doctors and general staff in hospitals of affected countries, 
local authorities as well as the governments of the countries which were affected by the Ebola outbreak 
within the period under review. 
 
 
2. RESEARCH METHOD  
This paper is based on secondary data. Research findings and publications of scientists in the field 
of medicine, especially those whose research have focused on Ebola since the first outbreak of the disease in 
1976, responses of ECOWAS and lessons going forward. In this article, I highlight key information found in 
more than forty journal articles, two books published after the 1967 outbreak of Marburg HF in Germany and 
Yugoslavia; and the 1976 epidemics of Ebola HF in Zaire and Sudan. I also consider published compendium 
of the filovirus literature: Martini G. A., 1971; 1978; Kuhn J. H., 2008, among others. I focus on the 
objective physical features of the disease caused by Marburg virus and by species of Ebola virus. It does not 
discuss Ebola Reston virus, which is not known to have caused disease in humans. It is argued that at the 
time of the research it had not seen much report and did not describe the phenomenon of “asymptomatic” 
infection in close contacts of Ebola HF patients [2]. Reports from some agencies that played a role in 
fighting, informing and educating Africans and the world at large have been studied. Information gleaned 
from these sources have been pieced together to form a systematic narrative on the disease. This commentary 
has been grouped into themes. They include the incubation period and physical examination, laboratory tests, 
typical case, disease update in 2014, guidelines, some efforts by international organizations including 
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3. RESULTS AND ANALYSIS  
3.1.  The science of ebola: incubation period and physical examination  
The most reliable information on the incubation period of Ebola has been obtained from situations 
in which a single well-defined event, such as a laboratory accident, contact with an infected animal,  
or exposure in a hospital, has occurred. This notwithstanding, the 2014 outbreak in countries like Guinea, 
Liberia, Sierra Leone and Nigeria which recorded great number of mortality has given the world scientists 
and laboratarians ample specimen. [3-4] The incubation period after a needle stick injury with Ebola Sudan 
virus was six days and it was seven days for a similar exposure to Ebola Zaire virus. Again, Formenty P. et al 
stressed that an ethologist who performed a necropsy on a dead chimpanzee in Côte D’Ivoire became ill eight 
days later. Also, two tourists who were exposed to bats while visiting the same cave in Uganda developed 
Marburg HF; one ten days and the other thirteen days later [5].  
During the first Marburg outbreak, incubation periods for infections resulting from well-defined 
exposures ranged from five to nine days, while outbreaks of Ebola Zaire HF have varied from 3 to 12 days 
[6]. Generally, these reports showed a trend of 3 to 13 days for the incubation period. All available reports 
agreed that Marburg and Ebola HF patients become ill abruptly with a variety of nonspecific signs and 
symptoms, including fever, chills, fatigue, headache, myalgia, nausea, vomiting, and diarrhoea. As a result of 
the earlier nonspecific nature of these findings, physicians in sub–Saharan Africa generally assumed that  
a febrile patient sufferred from malaria, typhoid fever, or other illness common to the region. Filoviral HF is 
usually not suspected until a rash or haemorrhage is noted or person-to-person transmission, especially 
among doctors and nurses, has occurred. Research findings from different scientists suggest that elevated 
body temperature is a characteristic feature of filoviral HF [3-5, 7-13].  
Also, the scientists and the laboratarians postulate that temperatures of 39°C to 40°C early in the 
course of the disease are mostly observed. The progression of fever over time has been displayed graphically 
in several articles [4, 6-8, 10, 14-16]. Wide swings in body temperature during the course of illness,  
which drops to below normal, have been described [3, 7, 9, 16]. Despite the utility of the blood pressure as a 
basic measure of cardiovascular status, the literature posit that actual values are mentioned in only a handful 
of reports, typically when a patient is first examined and the hemodynamic parameters are  
normal [4, 8-9, 12]. It is also reported that fatally infected patients are known to proceed through hypotension 
and shock to death, but blood pressure data during the course of illness have rarely  
been reported [4, 12-13, 17-19]. It is further reported that it is only in the case of a nurse in South Africa who 
became fatally infected with Ebola Zaire virus during patient care had data obtained through Swann-Ganz 
catheterization reported [19]. However, the published findings covered only day 18 of illness  
(which was five days before death) when the pulmonary artery occlusion pressure was 22 mm Hg and the left 
ventricular stroke work index and systemic vascular resistance were low.  
Although it has been argued that heart rates have rarely been included in case reports, some authors 
have noted that a pulse–temperature dissociation (relative bradycardia) is a common finding early in the 
course of filoviral HF [3-4, 6, 8, 12, 14, 17, 20]. The literature posits that as the illness progresses,  
patients may become tachycardic, with rates as high as 120–140 beats/min, especially late in the course of the 
disease. Regarding the first Marburg outbreak, Martini commented that tachycardia corresponding to the 
height of temperature was only found in fatal cases [6]. Different authors have also argued that,  
the respiratory rate is the vital sign least frequently documented in clinical reports [4, 8-9, 18]. As reported,  
in two cases, patients had rates of 24 and 20 breaths/min, respectively, on days 4 and 5 of illness [8-9].  
The two cases were febrile, and the first had an elevated pulse of 100 beats/min. Another individual whose 
condition was described as “extremely grave” on day 13 of illness had respiratory rates of 32–36/min when 
supine and 40/min when standing, with a pulse of 108 beats/min and blood pressure 90/60mmHg [8]. 
Accounts of the 1995 Ebola Zaire outbreak noted that tachypnea was present in 31 of 84 non-survivors,  
but none was found in the 19 survivors [13, 18]. 
Several descriptions of Marburg or Ebola HF note the development of rashes early in the course of 
illness. In a number of outbreak reports, a rash was seen in 25%–52% of individuals [3-10, 12-14, 16-24].  
It is frequently described as being non-pruritic, erythematous, and maculopapular, sometimes beginning 
focally, and then become diffused, generalized, and confluent. Others have described it as  
morbilliform– measles-like [14, 22] or scarletinoid [7]. The rash may be difficult to discern in dark-skinned 
individuals. The most reliable diagnostic sign was a characteristic rash. It began between the fifth and 
seventh day at the buttocks, trunk, and outside of both upper arms as a distinctly marked, pin-sized red 
papula around the hair roots. This stage lasted up to 24 hours and developed into a macular, papular,  
sharply delineated lesion which later coalesced into a more diffused rash [6]. 
As reported by the literature, patients with filoviral HF often develop multiple foci of mucosal 
hemorrhage, most evident in the conjunctiva, together with easy bruising and persistent bleeding from 
injection or venepuncture sites. However, haemorrhage is not seen in all patients, and massive bleeding is 
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usually observed only in fatal cases when it is typically localized to the gastrointestinal tract.  
Other abnormalities on physical examination of patients with filoviral HF that have been mentioned 
frequently in case descriptions or outbreak reports include pharyngeal erythema with a complaint of sore 
throat, enlarged lymph nodes, tender hepatomegaly with the edge of the liver below the ribcage, abdominal 
pain and tenderness to palpation [6-9, 13, 18-20, 22, 25-27]. 
 
3.2.  Ascertaining  
The literature posits that haemoglobin and haematocrit indices are rarely mentioned and have been 
recorded over the course of illness for only two patients. In the first case, no haemorrhage was described,  
and only a minor, transient decrease in haemoglobin and haematocrit was seen [16]. The other patient bled 
from injection sites, developed a haemorrhagic rash, and had a progressive decline in haemoglobin [16].  
The literature argues among others that patients with filoviral HF typically are leukopenia at the time of 
clinical presentation, with an abnormally low number of lymphocytes and an increased percentage of 
granulocytes [6, 9, 16, 19]. As the disease progresses, the total leukocyte count rises above normal, with an 
increase in immature granulocytes and the appearance of numerous atypical lymphocytes. In fatal cases, 
leukocytosis persists through to death. Also, thrombocytopenia is a constant feature of filoviral HF; it is 
present either at the time of clinical presentation or develops early in the course of illness In severely ill 
patients, the platelet count continues to decline, and in fatal cases it remains low until death [6, 9, 16, 19, 27].  
Again, elevated serum levels of alanine and aspartate aminotransferase (ALT, AST) are a common 
feature of Marburg and Ebola HF [4, 6-10, 14, 16, 19, 21]. However, peak serum concentrations of these 
enzymes are usually much lower than those seen in infections by viruses such as hepatitis A or B or yellow 
fever. In all but one report, the AST is higher than the ALT [8]. The serum alkaline phosphatase level,  
when reported, has been either normal or elevated, while the lactate dehydrogenase and gamma-
glutamyltransferase concentrations were elevated in the few instances when they were  
measured [4, 6, 16, 19, 21]. The serum total bilirubin level was mentioned in only four reports in which it 
was either normal or elevated [6, 9, 16, 28]. As noted above, jaundice is not a common feature of filoviral 
HF. Also, a study of 123 patients in the 2000 outbreak of Ebola Sudan HF in Uganda found that, mean AST 
values over the course of illness were significantly higher in fatal cases than in survivors. It is also revealed 
that the mean AST concentration was 7–12 times higher than the ALT in fatal cases and 2–4 times higher in 
nonfatal cases [4, 6, 9, 16, 19, 21].  
An earlier study has shown that serum electrolyte and glucose measurements have rarely been 
reported. In the 1967 Marburg HF outbreak, hypokalemia was seen in 50% of patients, typically coinciding 
with vomiting and diarrhoea [6]. Patients in the 2000 Ebola Sudan HF outbreak showed a decline in glucose 
levels on days 3 to 5 of illness that persisted beyond day 8. No difference was noted between fatal and 
nonfatal cases [28]. In contrast, a decrease in the serum calcium level to less than 6 mg/dL was associated 
with fatal illness. Again, renal function is generally normal at the time of presentation or in the early phase of 
illness, but by the end of the first week, patients may show a progressive decline in urine output and a rise in 
Blood Urea Nitrogen (BUN and creatinine) [4, 8, 16-19, 21, 28]. Two papers describe oliguria that did not 
improve despite the administration of intravenous fluids [12, 3]. Renal failure is more common in fatal cases. 
Hematuria and proteinuria have also been noted. In two cases in which patients were tested frequently for 
proteinuria, its presence appeared to correspond with fever [3, 7]. The need for renal dialysis is mentioned in 
two reports [19, 21].  
In addition, concerning pancreatic enzymes, a handful of articles mention pancreatitis without 
specifying its time course; when serum amylase concentrations are stated, they range from normal to elevated 
[4, 9, 16-17, 28]. Lipase levels have not been reported. Other related issues include coagulation parameters, 
terminal course, and duration of illness in fatal cases, convalescence, viremia and anti-body response.  
Several reports have described prolongation of the prothrombin time (PT), partial thromboplastin time (PTT), 
or bleeding time and other coagulation defects [6, 16, 19]. Patients with filoviral HF frequently meet the 
criteria for disseminated intravascular coagulation (DIC). In the 2000 outbreak of Ebola Sudan HF in 
Uganda, patients had elevated plasma levels of D-dimers, with markedly higher levels in fatal cases [28]. 
Reports generally state that patients dying of filoviral HF progress from prostration and obtundation to severe 
hypotension and shock, ending in coma [6-7, 18,22]. As noted above, few data have been published on the 
pulse, blood pressure, respiratory rate, and other physiological parameters during the final phase of illness.  
In 25 well-documented fatal cases of Marburg and Ebola HF, the majority of deaths occurred during the 
second week of illness, with a median survival of 9 days from onset of illness  
to death [4-7, 9, 12, 14, 19-20, 26, 29]. 
The only patient who died after day 16 suffered a terminal intracerebral haemorrhage while being 
treated in an intensive care unit [19]. The observation that persons who live through the second week of 
illness are likely to recover is consistent with a report from the 1995 Ebola Zaire HF outbreak that showed 
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that patients who were still alive on day 14 had more than 75% chance of survival [30]. From onset of illness 
to death in 25 well-documented fatal cases of Marburg and Ebola HF, the median survival is  
9 days [4-7, 9, 12, 14, 19-20, 26, 29].  
All descriptions of survivors of filoviral HF agree that recovery is prolonged, lasting weeks to 
months. Sequela of the acute illness include asthenia, weight loss, headache, dysesthesias, migratory 
arthralgias, sloughing of skin, loss of scalp hair, and persistent anaemia [3, 7-8, 10, 16, 18, 21, 26, 31].  
In a number of instances, acute orchitis or uveitis might have developed weeks after the resolution of acute 
illness, and virus was detected in samples of semen or aqueous humour [3, 6, 9, 31]. During the 1967 
Marburg HF outbreak, a convalescent male patient transmitted the virus to his wife, apparently through 
sexual intercourse [6]. Pathologic changes in fatal cases of filoviral HF are known from a few autopsies 
performed during the 1967 Marburg HF outbreak and in single cases and epidemics in Africa.  
In both Marburg and Ebola HF, the principal gross abnormality is the presence of multiple foci of 
haemorrhage. The most characteristic histopathologic finding is extensive hepatocellular necrosis,  
with eosinophilic inclusion bodies corresponding to aggregates of nucleocapsids seen by electron 
microscopy. The spleen and lymph nodes show a marked decrease in lymphocytes, variously described as 
follicular “necrosis” or “atrophy”, leaving residual cellular debris. Evidence of acute tubular necrosis, 
consistent with hypovolemic shock, is seen in the kidneys. Other organs show scattered foci of necrosis, 
edema, and other nonspecific changes [22, 32-35]. As argued elsewhere, because the clinical and laboratory 
features of filoviral HF are nonspecific, confirmation of the diagnosis requires detection of virus in a blood 
sample or the demonstration of a virus-specific antibody response.  
There is no evidence that persons infected with Ebola or Marburg virus are viremic during the 
incubation period. However, virus could be detected in blood samples on the onset of day of illness [36]. 
Serum levels of viral genomes, as detected by reverse transcription–polymerase chain reaction (RT-PCR), 
and of viral antigen, as detected by enzyme-linked immuno-sorbent assay (ELISA), increase during the first 
week of illness, and in fatal cases remain elevated until death [3-4, 31, 37-40]. Studies conducted during 
outbreaks in Gabon and Uganda found that titers of circulating viral genomes were significantly higher in 
fatalities than in nonfatal cases [36, 38-40]. In patients who survive infection, viremia usually becomes 
undetectable by the end of the second week of illness [31, 36-39]. However, infectious virus may persist in 
certain anatomic sites, such as the testes or the anterior chamber of the eye (see above). Also because 
immunofluorescence assays have a high positive background rate, the detection of antifilovirus antibodies 
has been based on ELISA since the 1995 Kikwit outbreak [36, 41]. Experiences during several large 
epidemics have shown that most fatally infected patients fail to develop an antibody response. The detection 
of virus-specific immunoglobin M (IgM) or G (IgG) in a serum specimen is therefore a favourable prognostic 
sign [31, 38]. When an IgM response occurs, it is generally detectable during the first week of illness,  
and peaks during the second week [36, 42]). Virus-specific IgG appears soon after the IgM. Limited reports 
indicate that IgG can be detected by ELISA in disease survivors for as long as 11 years [43-44].  
 
3.3.  Description of a typical case  
In general, articles published before the mid-1980s provide more detailed clinical information on 
patients with Marburg and Ebola HF than papers which have appeared since that time. The best sources of 
data on the clinical and laboratory features of filoviral HF are the numerous publications describing the 1967 
Marburg HF outbreaks in Germany and Yugoslavia and reports of individual cases of Marburg and Ebola 
Zaire virus infection treated in hospitals in Kenya and South Africa. Another case is the Ebola Côte d’Ivoire 
virus infection treated in Switzerland, and three accidental laboratory  
infections [3-4, 6-8, 10, 16-17, 19, 21, 25]. Considerable amounts of patient data were also obtained during 
the 2000 outbreak of Ebola Sudan HF in Uganda [28, 36, 40]. In contrast, most reports of epidemics in 
central Africa have provided either general descriptions of patients, summaries of signs and symptoms, or no 
clinical information at all. During the review of the literature, it was recorded that symptoms, such as fever, 
rash and thrombocytopenia, showed repeatedly in descriptions of patients with filoviral HF; these seem to 
have therefore been accepted as standard features of illness. In contrast, some other physical or laboratory 
findings were described in only one or few reports, and they could be considered to require further study or 
research. Although health workers responding to African epidemics have certainly monitored the pulse rate, 
blood pressure, and other physiological parameters of their patients, those data have unfortunately not been 
vigorously compiled and published [20]. 
Review of the published literature has shown that, although a number of features of filoviral HF are 
well defined, many aspects remain poorly characterized or incompletely documented. From the point of view 
of modern critical care medicine, the most significant gap in knowledge is the almost complete absence of the 
types of data that physicians have come to rely on in managing severely ill patients. These include basic 
parameters of cardiovascular function such as pulse, blood pressure, and urine output, and markers of 
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physiologic status such as the serum electrolytes, glucose, lactate, and PH. Impediments to collecting these 
data during past outbreaks have included their frequently remote location and limited resources and the 
traditional focus on outbreak control rather than patient care [11]. The hazard, real or perceived, of accidental 
exposure to the virus has also been a concern. In recent years, however, improved understanding of the 
specific modes of virus transmission and the standardization of personal protective equipment has lessened 
the risk to healthcare workers [11].  
Also, simpler and less invasive measures have been proposed; they include the regular recording of 
pulse, blood pressure, fluid intake, and urine output, together with careful record keeping. It is envisaged that 
this would go a long way toward improving the understanding of experts towards the clinical course of 
filoviral HF [20]. Again, continuous laboratory studies have been found to be another useful approach to 
understand the pathophysiology of filoviral HF, especially in nonhuman primates, which appear to closely 
replicate the fatal disease seen in humans [20, 45]. As described in another article, implanted telemetry 
devices have been used to monitor body temperature, pulse, systolic and diastolic blood pressure, and other 
parameters in macaques infected with Ebola Zaire virus [20]. 
 
3.4.  Disease updates on the 2014 Ebola outbreak  
New cases and deaths attributable to Ebola Virus Disease (EVD) continued to be reported by the 
Ministries of Health in Guinea, Liberia, Nigeria, and Sierra Leone. Between 2nd and 4th August 2014,  
108 new cases (laboratory-confirmed, probable, and suspect cases) of EVD and 45 deaths were reported from 
the four countries as follows: Guinea, 10 new cases and 5 deaths; Liberia, 48 new cases and 27 deaths; 
Nigeria, 5 new cases and 0 deaths; and Sierra Leone, 45 new cases and 13 deaths [46].  
By 4th August 2014, the cumulative number of cases attributed to EVD in the four countries stood 
at 1,711, including 932 deaths. The distribution and classification of the cases as shown in Table 1 were as 
follows: Guinea, 495 cases (351 confirmed, 133 probable, and 11 suspected), including 363 deaths;  
Liberia, 516 cases (143 confirmed, 252 probable, and 121 suspected), including 282 deaths; Nigeria, 9 cases  
(0 confirmed, 2 probable, and 7 suspected), including one death; and Sierra Leone, 691 cases (576 confirmed, 
49 probable, and 66 suspected), including 286 deaths [46].  
 
 
Table 1. Confirmed, probable, and suspected cases and deaths from Ebola Virus Disease (EVD) in Guinea, 
















New cases were reported between 2nd and 4th August 2014. The total number of cases was subject 
to change due to ongoing reclassification, retrospective investigation, and availability of laboratory results. 
Data reported in the Disease Outbreak News are based on official information reported by Ministries of 
Health [46].  
 
3.4.1. Brussels/Geneva, 22nd March 2014  
An outbreak of EVD in southern Guinea prompted the international medical organization, Médecins 
Sans Frontières (MSF), to launch an emergency response. Twenty-four MSF doctors, nurses, logisticians and 
hygiene and sanitation experts were deployed, while additional staff strengthened the team in the days which 
ensued. MSF set up an isolation unit for suspected cases in Guéckédou, in collaboration with the Ministry of 
Health, and did same in the town of Macenta, also in the Nzérékoré region in the south of the country.  
Dr Esther Sterk, the MSF tropical medicine advisor is reported to have said that “Isolation units are essential 
to prevent the spread of the disease, which is highly contagious”. Specialized staff provided care to patients 
 New Confirmed Probable Suspect Total (by Country) 
Guinea      
Cases 10 351 133 11 495 
Deaths 5 228 133 2 363 
Liberia      
Cases 48 143 252 121 516 
Deaths 27 128 110 44 282 
Nigeria      
Cases 5 0 2 7 9 
Deaths 0 0 1 0 1 
Sierra Leone      
Cases 45 576 49 66 691 
Deaths 13 247 34 5 286 
Totals      
Cases 108 1070 436 205 1711 
Deaths 45 603 278 51 932 
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showing signs of infection. With the help of the local community, MSF’s emergency team also focused on 
actively searching for people who might have been infected through contact with already identified  
EVD patients [46].  
Within the period, MSF also sent some 33 tons of supplies to Guinea on two chartered airplanes 
departing from Belgium and France, which contained medicines, medical equipment and the supplies 
necessary for isolating patients, putting sanitation measures in place and protecting its teams. Within the 
earlier periods of their stay, 49 suspected cases were registered by the Ministry of Health in Guinea. Six cases 
were confirmed and 29 people have died. Essentially, the attestation of the impact of Ebola on these 
communities cannot be overemphasized. Also, it emphasizes the importance of these organizations that have 
persistently and continuously made significant interventions in the area of health and related social 
challenges affecting countries [46]. 
 
3.5.  Analyses on reports on 2014 outbreak  
The Guinean Ministry of Health, the Ministry of Health and Sanitation in Sierra Leone, the Ministry 
of Health and Social Welfare of Liberia, and the Nigeria Ministry of Health have been working with national 
and international partners to investigate and respond to the outbreak of the disease in 2014. The outbreak 
update since 2014 has been very alarming. It further suggests that the West-African region mostly affected 
were unable to easily stem the tide of the disease which has the potential to cause a world health menace.  
Tropical and non-tropical epidemics have crossed the boundaries of sovereign nations. Bacteria, 
fungus or viral diseases with their human or animal host (in cases where it is zoonotic) has proven that when 
responsible and responsive actions are not taken by African governments in partnership with global 
organizations like the World Health Organization, the continent could live under a strange disease terror 
harsher than any insurgent group. Disease mutation could be harsher than the mutation of a nascent armed 
human guerrilla group in a particular political setting in a sovereign country. The records as of August 8, 
2014 showed a certain level of gloom.  
The World Health Organization, in partnership with the Ministries of Health in Guinea,  
Sierra Leone, Liberia, and Nigeria announced a cumulative total of 1779 suspected and confirmed cases of 
EVD and 961 deaths, as of August 6, 2014. Of the 1779 clinical cases, 1134 cases were laboratory-confirmed 
for Ebola virus infection. In Guinea, 495 cases, including 367 fatal cases and 355 laboratory confirmations 
were reported by the Ministry of Health of Guinea and WHO as of August 6, 2014. Active surveillance 
continued in Conakry, Guéckédou, Pita, Siguiri, Kourourssa, Macenta, and Nzerekore Districts. In Sierra 
Leone, WHO and the Ministry of Health and Sanitation reported a cumulative total of 717 suspected and 
confirmed cases of EVD as of August 6, 2014. Out of this number, 631 cases were laboratory-confirmed and 
298 were fatal. All districts reported clinical EVD patients. Reports, investigations, and testing of suspect 
cases continued across the country [46].  
By August 6, 2014, the Ministry of Health and Social Welfare of Liberia and WHO reported 554 
clinical cases of EVD, including 148 laboratory confirmations and 294 fatal cases. Suspect and confirmed 
cases were reported in 9 of 13 counties. Laboratory testing was conducted in Monrovia. In Nigeria, WHO 
and the Nigerian Ministry of Health reported 13 suspect cases, including two fatal cases, as of August 6, 
2014. The Centre for Disease Control and Prevention (CDC) was in regular communication with the 
Ministries of Health (MOH), WHO, MSF, and other partners regarding the outbreak. CDC had personnel in 
all four countries assisting the respective MOHs and the WHO-led international response to the Ebola 
outbreak. It seems to me, however that the debate concerning the lack of prompt response by the local people 
and international response seems to sometimes overshadow the discourse on the efforts as well as the 
gallantry displayed by the indigenous physicians who were on the frontline and died through their efforts to 
save their countrymen. It is quite clear from what saturates the reports on the efforts of respective institutions 
that there was some degree of coordination and support from within and without to deal with the scourge of 
the diseases in the end. What remains at this critical juncture is the question of the recurrence of the diseases 
whose experts are likely to remain in Europe and elsewhere in the Americas [46]. 
 
3.6.   Guidelines for flights  
3.6.1. Interim guidance about evd for airline crews, cleaning personnel, and cargo personnel  
The prevention of EVD includes measures to avoid contact with blood and body fluids of infected 
individuals and with objects contaminated with these fluids (e.g., syringes) and stopping ill travelers from 
boarding aircrafs. People who have been exposed to Ebola virus disease should not travel on mercial 
airplanes until there is a period of monitoring for symptoms of illness lasting 21 days after exposure.  
Sick travelers should delay travel until cleared to travel by a doctor or public health authority [47].  
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3.6.2. Management of Ill people on aircraft if ebola virus is suspected  
The following precautions have been prescribed if an ill-traveler (passenger or crew) has symptoms 
consistent with Ebola and was recently in a country with Ebola: keep the sick person separated from others as 
much as possible, provide the sick person with a surgical mask (if the sick person can tolerate wearing one) 
to reduce the number of droplets expelled into the air by talking, sneezing, or coughing, give tissues to a sick 
person who cannot tolerate a mask and provide a plastic bag for disposing of used tissues as well as the 
wearing of impermeable disposable gloves for direct contact with blood or other body fluids [47].  
 
3.6.3. Universal precaution kits  
Airplanes travelling to countries affected with Ebola have been encouraged to carry Universal 
Precaution Kits (UPK), as recommended by the International Civil Aviation Organization (ICAO),  
for managing ill on-board passengers [47]. 
 
3.6.4. Reporting Ill travellers  
With the United States, the captain of an aircraft is required by law to report to the Centres for 
Disease Control and Prevention (CDC) before arrival any deaths on-boards or ill travellers who meet 
specified criteria. This is consistent with mandatory reporting requirements of ICAO (ICAO document 4444 
of the Chicago Convention; Chapter 8, Annex 9). CDC staff can be consulted to assist in evaluating an ill 
traveller, provide recommendations, and answer questions about reporting requirements.  
However, reporting to CDC does not replace usual company procedures for in-flight medical consultation or 
obtaining medical assistance. CDC routinely conducts contact investigations to alert other passengers and 
crew of their exposure to ill travellers with certain diseases who were possibly contagious on their flight [47].  
 
3.6.5. What to do if you think you have been exposed  
Any airline crew, cleaning or a cargo personnel who thinks he could be exposed to Ebola either 
through travel, assisting an ill traveller, handling a contaminated object, or cleaning a contaminated aircraft 
should take the following precautions: Notify your employer immediately, monitor your health for 21 days. 
Watch for fever (temperature of 101.5°F/38.6°C or higher), severe headaches, muscle aches, diarrhoea, 
vomiting, rash, and other symptoms consistent with Ebola [47].  
 
3.6.6. When to see a health care provider  
When sudden fever, chills, muscle aches, severe diarrhea, vomiting, rash, or other symptoms 
consistent with Ebola is detected, you should seek immediate medical attention. Before visiting a health care 
provider, alert the clinic or emergency room in advance about your possible exposure to Ebola virus so that 
arrangements can be made to prevent spreading it to others. When traveling to a health care provider,  
limit contact with other people. Do not embark on any travel for any purpose travelling the see the doctor.  
If you are located abroad, contact your employer for help with locating a health care provider.  
Resident embassies or consulates in the country where you are located can also provide names and addresses 
of local physicians [47].  
 
3.6.7. Guidance for airline cleaning personnel  
Treat any body fluid as though it is infectious. Blood or body fluids on interior surfaces can spread 
Ebola if they get into your eyes, nose, or mouth. Therefore, hand hygiene is the most important infection 
control measure. Wear disposable impermeable gloves when cleaning visibly contaminated surfaces. For any 
ill traveller on board an aircraft, even if Ebola is not considered, the airline's ground and cleaning crews have 
been encouraged to be notified so that preparations could be made to clean the aircraft after passengers have 
disembarked. When cleaning an aircraft that has carried a purported Ebola patient, personnel have been 
advised to follow the following precautions: They are encouraged to wear impermeable disposable gloves 
while cleaning the passenger cabin and lavatories, wipe down lavatory surfaces and frequently touched 
surfaces in the passenger cabin, such as armrests, seat backs, tray tables, light and air controls, and adjacent 
walls and windows with an Environmental Protection Agency (EPA) registered cleaner/disinfectant that has 
been tested and approved for use by the airplane manufacturers, special cleaning of upholstery, carpets, or 
storage compartments is not indicated unless they are obviously soiled with blood or body fluids and special 
vacuuming equipment or procedures are not necessary. The others include: not using compressed air, which 
might spread infectious material through the air, if a seat cover or carpet is obviously soiled with blood or 
body fluids, it should be removed and discarded by the methods used for biohazardous material, throw used 
gloves away according to the company's recommended infection control precautions when cleaning is done 
or if they become soiled or damaged during cleaning and finally among other things; clean hands with soap 
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and water (or waterless alcohol-based hand sanitizer when soap is not available) immediately after gloves  
are removed [47]. 
 
3.6.8. Guidance for air cargo personnel  
Packages should not pose a risk. Ebola virus is spread through direct contact with blood or body 
fluids (such as urine or saliva) from an infected person. Packages visibly soiled with blood or body fluids 
should not be handled. Cargo handlers have been encouraged to wash their hands often to prevent other 
infectious diseases [47].  
 
 
4. SOME EFFORTS by INTERNATIONAL ORGANIZATIONS INCLUDING ECOWAS  
thus FAR  
In countries like Sierra Leone, and Liberia, several global efforts were made by world bodies like 
the World Health Organization (WHO) and other Non-Governmental Organizations and groups to stem the 
tide of the disease. The WHO report in 2015 estimated that ten thousand (10,000) people were killed by the 
disease in West Africa [48]. A mission briefing with representatives from Member States was held on 5th 
August 2014, at the World Health Organization (WHO). Information about the nature of EVD was 
highlighted. This was followed by outlining the essential components for control, including the need for 
national leadership, improved care and case management, identifying transmission chains and stopping 
disease spread, and preventing further outbreaks. Among the critical issues are cross-border infections and 
travellers; partners reaching the limits of their capacity and ability to respond rapidly, safely, and effectively, 
and concerns about the socio-economic impact of continued transmission [46].  
The Director-General of WHO also shared information from her meetings in Guinea with Member 
States of the Mano River Union–Côte d’Ivoire, Guinea, Liberia, and Sierra Leone. She noted that the 
response in West Africa would focus on three areas; that is treatment of Guéckédou, Kenema, and Foya as  
a unified sector, which included public health measures meant to reduce movement in and out of the area as 
well as the intensification of current measures in Guinea, Liberia, Nigeria, and Sierra Leone [46].  
Taking steps to reduce international spread to other countries in Africa and outside of the African Region, the 
Sub-Regional Ebola Operations Coordination Centre (SEOCC) in Conakry reported on 5th August that the 
following actions were to be taken in the four affected countries: In Guinea, new foci emerged and case 
management facilities were needed. Exit screening was tested in Conakry, in partnership with the US CDC. 
In Liberia, security issues continued to be of concern. Notwithstanding the commitment of the government, 
community resistance remained high. Also, in Nigeria, the government focused on following up the contacts 
from the index case. Clinical support was urgently needed and a treatment centre was set up for managing 
cases of EVD. Again, in Sierra Leone, efforts were made to map where treatment centres were most needed 
and setting them up. A similar exercise was also underway for laboratories [46].  
The SEOCC also assisted countries with these and many other response measures. Within the plans 
of WHO was the convening of an emergency committee of international experts to review the outbreak and 
advise the Director-General on whether the EVD outbreak constituted a Public Health Emergency of 
International Concern (PHEIC) [46]. This was to be done in accordance with the International Health 
Regulations. Experts were to receive an epidemiological briefing and determine whether the criteria for  
a PHEIC have been met which had the propensity to necessitate the briefing of the Director-General on 
temporary recommendations [46]. To emphasize, as stated elsewhere in this study, though there were some 
indigenous efforts which would be emphasized in the next section, the debate is that; though Africa hosts the 
disease, experts of EVD might remain elsewhere in Europe or the Americas. Ebola experts are likely to be 
located outside Africa and Africans would become increasingly dependent on foreign expertise. The WHO, 
United Nations, Medicines Sans Frontieres, Samaritans Purse, International Medical Purse, Canadian Red 
Cross, Partners in Health and USAID recruited a relevant number of staff but did not pay attention to the 
possibility of future dependence on equitable economic and geographic representation [48]. The territory 
affected by Ebola just to emphasize, have also persistently suffered from recurrent cholera, measles, 
meningitis and lassa fever which continuously undermined the weak health systems of these countries [48].  
Again, in Sierra Leone, the National Ebola Response Centre (NERC) was funded by the UK’s 
Department of International Development (DFID) with an additional support from the US based Centres for 
Disease Control and Prevention (CDC) and the United Nations Missions for Ebola Emergency Response 
(UNMEER). Though the persistent fall-back on old colonial powers and their agencies or institutions have 
been critiqued by some scholars, it seems to me that the people of Sierra Leone and other affected countries 
during the Ebola crisis in 2014-2015 respectively had no better financial and human capital options than the 
international assistance including additional human and financial resources among other things that came 
through the afore stated organizations [49]. However, Sisay has argued that, the importance of local 
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ownership and decentralizing decision-making was very crucial in dealing with the Ebola question. 
Notwithstanding, the financial and human resources provided by these international organizations and 
respective agencies from foreign countries, the impact on the citizenry and the affected population in 
particular was strong in instances when they were deployed in partnership with local agencies  
and communities [50]. 
The existing literature posit that in Sierra Leone for instance, there was the need for the Ministry of 
Health, and the Sierra Leones’s National Ebola Response Centre (NERC) to play an important role in 
countering the outbreak of Ebola that afflicted Liberia, Guinea and Sierra leone within 2014 and 2015 
respectively [51]. Again, it is important to emphasize that the efforts of the Sierra Leonean president,  
Ernest Bai Koroma and OB Sisay, Director of the Situation Room of NERC cannot be gainsaid. These initial 
efforts by NERC systematically put in place strategies and structures to support those who were making 
efforts to reduce the spate of infection and stop the outbreak. This notwithstanding, the literature highlights 
the ineptitudeness of the Ministry of Health and Sanitation in Sierra Leone. It is argued among other things 
that the inability of the Ministry to deliver led to the sack of the minister of Health and Sanitation  
in August 2014 [50].  
In Liberia, the government reactivated a pre-existing Task Force within the Ministry of Health and 
Social Welfare in late March 2014, when the first diagnoses of Ebola were made. President Johnson Sirleaf 
declared a State of Emergency on 6th August and on 10th August appointed the Assistant Minister of Health 
and Social Welfare, Tolbert Nyenswah, as Head of the Incident Management System. The Liberian 
authorities invited international experts to work directly within their government structures, and received 
advice and support from international organizations like the WHO among others. Local and religious leaders 
in parts of Liberia decided to “self-quarantine”, an initiative that was reported as more effective than district 
or individual level quarantine [51]. 
Significantly, there were several summits that were held by ECOWAS and more so, there were 
several decisions that were implemented by ECOWAS using its agency WAHO. For example,  
the 6th November 2014 ECOWAS Heads of State and Government Summit discussed the status of Ebola 
epidemic and made some recommendations to member states. Also, WAHO sent circulars to all health 
ministers within ECOWAS indicating the immediate measures to be taken to prevent and contain the 
epidemic [51]. This among other things included plans which focused mainly on health interventions:  
An agreement between WAHO,WHO, and AFDB signed on 19th May 2014 approved a sum of $3,091,136 
to provide urgent assistance for the fight against Ebola in Guinea and neighboring countries like Cote 
Divoire, Gambia, Guinea Bissau, Liberia, Mali, Senegal and Sierra Leone. The 45th Summit of ECOWAS 
Heads of States and Government on 10th and 11th July 2014 saw Nigeria and Cote DÍvoire giving  
$3.5 million and $1 million respectively to support the fight against Ebola [51].  
To emphasize, the Accra Response Strategy agreed upon by health ministers from eleven  
West-African countries on July 2014 and the “Ebola Response Roadmap” published by the WHO on 28th 
August, 2014 were very useful. The Accra Response Strategy was based the following strategic actions: 
Immedicate outbreak response interventions, enhanced coordination and collaboration as well as the scale-up 
of human and financial resource mobilization. Also, the WHO roadmap emphasized the use of 
complementary and controversial approaches to be used in areas with severe transmission to reduce the 
pressure on the population due to the outbreak with specific targets and timelines. These would form the 
bases for UN STEPP strategy which was launched on 16th September 2014 which aimed among other things 
to stop the outbreak, treat the infected, ensure essential services, preserve stability and prevent outbreaks in 
countries that were unaffected. These in essence provided an enduring, broad and flexible  
framework for operations [52].  
 
 
5. CONCLUSION   
The outbreaks in the respective countries in 2014-2015 saw several responses. These included 
national technical working groups, pillars or clusters which were established to deal with key components of 
the response. These covered issues which were identified as national priorities, which included case 
management, safe and dignified burials as well as surveillance and laboratory operations.  
Significantly, over time, they were adapted to the lines of action for the response, with additional emphasis 
on infection prevention and control, and on research and development. Countries developed additional 
structures to adapt to the national context as you will find in Sierra Leone and Liberia within the period under 
review. Key contributions were led by the countries, most especially by their community organizations.  
The leadership of the national governments of the affected countries, their preparedness and mostly their 
openness to embrace different sources of international support cannot be gainsaid. Though an anathema to 
expected homegrown strategies as discussed in different but broader discourses on Africa’s development 
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concerning her relationship with Europe with its surrogate institutions; discussions like this ought to give 
praise to which praise is due. In the broader scheme of things, the efforts of International Non-Governmental 
Organizations (NGOs) cannot be precluded on the basis of Africa’s intellectual and national jingoists.  
The above notwithstanding, as elucidated elsewhere in this current contribution, the Ebola response 
workforce within the period under review were largely national personnel which included volunteers through 
the national Red Cross Societies and faith groups among others. The challenge however, is the re-emergence 
of the disease. A one time antidote to reduce the degree of epidemicity and pandemicityshould suffice.  
It seems however, that, a declaration of a region free from the Ebola disease does not suggest the finality of 
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